Company profile
APNIMED, INC.
NASDAQ:APMDBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| ATOMOXETINE | phase3 | — | 3 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (13)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04631107 | phase2 | completed | 2020-12-22 | 2021-05-31 | Apnimed | AD109 Dose Finding in Mild to Moderate OSA |
| NCT05793684 | phase2 | completed | 2023-04-28 | 2023-11-09 | Apnimed | AD816 Crossover Study |
| NCT06566820 | phase3 | enrolling_by_invitation | 2024-07-03 | 2026-06-30 | Apnimed | Continuation Protocol for Obstructive Sleep Apnea (OSA) |
| NCT04445688 | phase2 | completed | 2020-07-15 | 2020-12-01 | Apnimed | Crossover Trial of AD036 in Obstructive Sleep Apnea |
| NCT04580394 | phase2 | completed | 2020-10-27 | 2021-05-28 | Apnimed | Crossover Trial of AD109 in Obstructive Sleep Apnea |
FDA applications (0)
No records yet.